Vaccitech plc (VACC)

2.9500 -0.1000 (-3.28%) At close: 04:00PM EST

Vaccitech plc

The SchrOedinger Building
Heatley Road The Oxford Science Park
Oxford OX4 4GE
United Kingdom
44 1865 818 808
https://www.vaccitech.co.uk

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 72

Key executives

Name	Title	Pay	Exercised	Year born
Mr. William J. Enright MBA	CEO & Director	754.28k	N/A	1963
Dr. Margaret Marshall M.D.	Chief Medical Officer	547.97k	N/A	1957
Ms. Sarah Gilbert	Co-Founder	N/A	N/A	N/A
Mr. Adrian Hill Ph.D.	Co-Founder & Scientific Advisor	N/A	N/A	N/A
Ms. Gemma Brown	Chief Financial Officer	N/A	N/A	N/A
Mr. Chris Ellis	Chief Operating Officer	N/A	N/A	1960
Dr. Thomas George Evans M.D.	Chief Scientific Officer	N/A	N/A	1955
Mr. Graham Griffiths	Chief Bus. Officer	N/A	N/A	1979
Ms. Elizabeth Eagling-Vose M.B.A.	Head of Clinical Operations	N/A	N/A	N/A
Bernie McDonald	Head of IP	N/A	N/A	N/A

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.

Corporate governance

Vaccitech plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.